सभी अध्ययन
भर्तीचरण1, चरण2हस्तक्षेपात्मक

फ्रंटोटेम्पोरल डिमेंशिया (FTD-GRN) के एक आनुवंशिक उप-प्रकार वाले विषयों में जीन थेरेपी उत्पाद AVB-101 की सुरक्षा और प्रभाव का मूल्यांकन करने के लिए एक अध्ययन

This research is looking into a new gene therapy called AVB-101 for a specific type of dementia called Frontotemporal Dementia with Progranulin Mutations (FTD-GRN). This condition affects younger people and leads to problems with a brain protein called progranulin. The study wants to find out if AVB-101 is safe, can restore this protein to normal levels, and potentially slow down the disease. All participants will receive a one-off treatment delivered directly to the brain, and doctors will monitor them for five years. The study involves people aged 30 to 75 who have FTD-GRN and meet specific health requirements.

एक नजर में

स्थिति
भर्ती
चरण
चरण1, चरण2
प्रायोजक
AviadoBio Ltd
नामांकन लक्ष्य
18
प्रारंभ
30 अगस्त 2023
अनुमानित पूर्णता
21 Mar 2030

यह अध्ययन किस बारे में है?

This study is looking into a new treatment for a specific type of dementia called Frontotemporal Dementia with Progranulin Mutations, or FTD-GRN. FTD is a brain condition that gets worse over time and can affect a person's behaviour, speech, and movement.

In FTD-GRN, these problems happen because there isn't enough of a vital protein called progranulin in the brain. This lack of protein causes brain cells to die, which then affects how the brain works. The new treatment, called AVB-101, is a type of 'gene therapy'. This means it's designed to help the body make more of the missing progranulin protein.

The main goals of this study are to: 1) check if AVB-101 is safe for people with FTD-GRN, 2) see if it can bring progranulin levels back to normal in the brain, and 3) explore if it can help slow down or even stop the disease from getting worse. This is an early-stage study, meaning it's one of the first times this treatment is being tested in people.

मुख्य निष्कर्ष

  • This study is for people with a specific type of Frontotemporal Dementia called FTD-GRN.
  • It's testing a new gene therapy, AVB-101, to see if it's safe and can help raise progranulin levels.
  • Participants will receive a one-time treatment delivered directly into the brain.
  • The study lasts for five years after the treatment.
  • There's no placebo; everyone gets the active treatment.
  • It's an early-stage study, so the full effects and risks are still being learned.

कौन पात्र हो सकता है?

The study is looking for both men and women between the ages of 30 and 75. To be considered, you must have been diagnosed with Frontotemporal Dementia due to a specific genetic change (a GRN mutation).

Doctors will also check how your dementia is affecting you, looking for certain signs related to changes in behaviour or language. You must also be able to follow all the study instructions and attend appointments, and you'll need to have a chosen study partner who can help support you and provide information during the study.

There are also some reasons why you might not be able to join. For example, if your dementia is very severe, or if you have other health conditions that could affect your brain or make the treatment unsafe. You also can't have had certain other experimental treatments or gene therapies before.

क्या यह अध्ययन आपके लिए उपयुक्त हो सकता है?

यह देखने के लिए इन त्वरित प्रश्नों का उत्तर दें कि क्या आप पात्र हो सकते हैं। यह केवल एक मार्गदर्शिका है — अंतिम निर्णय शोध टीम द्वारा लिया जाता है।.

  1. Are you between 30 and 75 years old?
  2. Have you been diagnosed with Frontotemporal Dementia caused by a GRN gene mutation?
  3. क्या आप सभी अध्ययन यात्राओं में भाग लेने और निर्देशों का पालन करने में सक्षम और इच्छुक हैं?
  4. Do you have a family member or friend who can be your 'study partner'?
  5. Do you have any other serious health conditions that might prevent you from joining?
  6. Have you had any other gene therapy or similar experimental treatments before?
अपने परिणाम देखने के लिए हर प्रश्न का उत्तर दें।.

भागीदारी में क्या शामिल है?

If you join this study, you won't receive a 'dummy' treatment; everyone will receive the actual study treatment, AVB-101. This treatment is given just once, directly into the brain through a procedure. After this single treatment, doctors will closely monitor your health and how you're responding for a period of five years. This will involve regular check-ups, tests, and assessments to see how you are doing.

संभावित जोखिम और लाभ

Participating in research studies like this can have potential benefits, such as gaining access to a new, experimental treatment that might help with your condition, and contributing to medical knowledge benefiting others. However, there are also potential risks involved, including those related to the procedure to deliver the treatment, and possible side effects from AVB-101 itself, which are not yet fully known. It's very important to remember that you have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

स्थान (19)

  • The Ohio State University (OSU) Wexner Medical Center
    सत्यापित पोस्टकोड
    कोलंबस, संयुक्त राज्य अमेरिका· भर्ती
  • Vanderbilt University Medical Centre
    सत्यापित पोस्टकोड
    नैशविल, संयुक्त राज्य अमेरिका· भर्ती
  • Houston Methodist Hospital
    सत्यापित पोस्टकोड
    ह्यूस्टन, संयुक्त राज्य अमेरिका· भर्ती
  • UZ Leuven
    सत्यापित पोस्टकोड
    ल्यूवेन, बेल्जियम· भर्ती
  • सनीब्रुक स्वास्थ्य विज्ञान केंद्र
    सत्यापित पोस्टकोड
    टोरंटो, कनाडा· भर्ती
  • Fondazione IRCCS Istituto Neurologico Carlo Besta
    सत्यापित पोस्टकोड
    मिलान, इटली· भर्ती
  • Amsterdam UMC
    सत्यापित पोस्टकोड
    एम्स्टर्डम, नीदरलैंड्स· भर्ती
  • NEURO-CARE Sp. z o.o. Sp. Komandytowa
    सत्यापित पोस्टकोड
    Katowice, Poland· भर्ती
  • Neurologia Slaska Centrum Medyczne
    सत्यापित पोस्टकोड
    Katowice, Poland· भर्ती
  • Uniwersyteckie Centrum Kliniczne, SUM w Katowicach
    सत्यापित पोस्टकोड
    Katowice, Poland· भर्ती
  • Euromedis Sp. z o.o.
    सत्यापित पोस्टकोड
    श्चेचिन, पोलैंड· भर्ती
  • Centrum Medyczne NeuroProtect Sp z o.o.
    सत्यापित पोस्टकोड
    Warsaw, Poland· भर्ती

सामान्य प्रश्न

What is FTD-GRN?

FTD-GRN is a type of Frontotemporal Dementia caused by a change in a specific gene, leading to low levels of a protein called progranulin in the brain.

What is gene therapy?

Gene therapy is a new kind of treatment that aims to correct problems with genes to help the body work correctly, in this case, by hopefully increasing progranulin protein levels.

Is AVB-101 a cure for FTD-GRN?

AVB-101 is an experimental treatment being studied to see if it can help treat FTD-GRN, but it is not yet known if it can cure the condition.

Will I get a placebo in this study?

No, there is no placebo in this study. All participants will receive the active study treatment, AVB-101.

मैं इस अध्ययन में कितने समय तक शामिल रहूँगा?

After receiving the one-time treatment, you will be monitored by the study team for five years.

और अधिक जानने के लिए कैसे पता करें

AviadoBio Clinical Trials

किसी अध्ययन में भाग लेने का निर्णय लेने से पहले हमेशा अपने जीपी या विशेषज्ञ से बात करें।.

भाग लेने में रुचि रखते हैं?

अपनी रुचि दर्ज करें

अपने विवरण साझा करें और अनुसंधान टीम के लिए "A Study to Evaluate the Safety and Effect of AVB-101, a Gene…यदि आप पात्र हो सकते हैं तो आपसे संपर्क करेंगे। भाग लेने के लिए सहमति देने से पहले हमेशा अपने जीपी से बात करें।.

चर्चा

समुदाय चर्चा

हमारे फोरम द्वारा संचालित community.patient.info. कृपया सम्मानजनक रहें — यह चिकित्सा सलाह नहीं है।.